ALX Oncology gets EC’s orphan drug status for evorpacept in gastric cancer
ALX Oncology Holdings, an Australian immuno-oncology company focusing on CD47 checkpoint pathway blocking therapies, declared a significant milestone with its flagship drug candidate evorpacept securing the European Commission’s (EC) orphan drug designation (ODD). This key approval marks a turning point in the treatment for patients suffering from gastric cancer, including gastric cancer and gastroesophageal junction […]